FDA APPROVES NEW CLASS OF MEDICINES TO TREAT PEDIATRIC TYPE 2 DIABETES
20/06/2023
Leggi
Breaking news
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Zhang L, Zhang Y, Shen S, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00132-8.
Leggi
Effect of multifactorial intensive treatment in patients with diabetic kidney disease: A meta‐analysis with trial sequential analysis
Shan J, Xu Z
Diabetes Obes Metab. 2023;25(8):2163-2170.
Leggi
The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials
Bjorner JB, Larsen S, Lübker C, Holst-Hansen T
Diabetes Obes Metab. 2023;25(8):2142-2150.
Leggi
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial
Svanevik M, Lorentzen J, Borgeraas H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00127-4.
Leggi
Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study
Larose S, Filliter C, Platt RW, et al.
Diabetes Obes Metab. 2023;25(8):2279-2289.
Leggi
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
Kang A, Smyth B, Neuen BL, et al.
Diabetes Obes Metab. 2023;25(8):2151-2162.
Leggi
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Liane Ong K, Stafford LK, McLaughlin SA, et al.
Lancet. 2023;S0140-6736(23)01301-6.
Leggi
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, et al.
The Lancet 2023. Pub. online 23 June 2023.
Leggi